Hyperlipidemia in Children After Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 25, Issue 10, 2006, Pages 1199-1205

  Singh, Tajinder P ^a   Naftel, David C ^b   Webber, Steven ^c   Dupuis, Joanne ^d   Chin, Clifford ^e   Spicer, Robert ^f   Schowengerdt Jr , Kenneth O ^g   Ring, W Steves ^h   Morrow, W Robert ⁱ  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^e STANFORD UNIVERSITY   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISONE; TRIACYLGLYCEROL;

ARTICLE; CARDIAC GRAFT REJECTION; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ADOLESCENT; CHILD; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INCIDENCE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 33749606663     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.06.003     Document Type: Article

References (36)

1. Taylor D.O., Edwards L.B., Boucek M.B., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report-2005. J Heart Lung Transplant 24 (2005) 945-955
2. Boucek M.B., Edwards L.B., Keck B.M., et al. Registry of the International Society for Heart and Lung Transplantation: eighth official pediatric report-2005. J Heart Lung Transplant 24 (2005) 968-982
3. Pahl E., Naftel D.C., Kuhn M.A., et al. The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study. J Heart Lung Transplant 24 (2005) 645-651
4. Dent C.L., Canter C.E., Hirsch R., and Balzer D.T. Transplant coronary artery disease in pediatric heart transplant recipients. J Heart Lung Transplant 19 (2000) 240-248
5. Derhaag J.G., Duijvestijn A.M., Damoiseaux J.G., et al. Effects of antibody reactivity to major histocompatibility complex (MHC) and non-MHC alloantigens on graft endothelial cells in heart allograft rejection. Transplantation 69 (2000) 189-190
6. Cantin B., Wen P., Zhu D., et al. Transplant coronary artery disease: a novel model independent of cellular alloimmune response. Circulation 104 (2001) 2615-2619
7. Hoang K., Chen Y.D., Reaven G., et al. Diabetes and dyslipidemia: a new model for transplant coronary artery disease. Circulation 97 (1998) 2160-2168
8. Kemna M.S., Valantine H.A., Hunt S.A., et al. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 128 (1994) 68-72
9. Fang J.C., Kinlay S., Beltrame J., et al. Effects of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomized trial. Lancet 359 (2002) 1108-1113
10. Kobashigawa J.A., Katznelsen S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
11. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96 (1997) 1398-1402
12. Valantine H. Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 14 suppl (1995) S234-S237
13. Rickenbacher P.R., Kemna M.S., Pinto F.J., et al. Coronary artery intimal thickening in the transplanted heart. An in-vivo intracoronary ultrasound of immunologic and metabolic risk factors. Transplantation 61 (1996) 46-53
14. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. JAMA 38 (2001) 206-213
15. Pahl E., Zales V.R., Fricker F.J., et al. Post-transplant coronary artery disease in children. A multicenter national survey. Circulation 90 suppl (1994) II-56-II-60
16. Sigfusson G., Fricker J.F., Bernstein D., et al. Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five years. J Pediatr 130 (1997) 862-871
17. Chin C., Rosenthal D., and Bernstein D. Lipoprotein abnormalities are highly prevalent in pediatric heart transplant recipients. Pediatr Transplant 4 (2000) 193-199
18. Armstrong A.K., Goldberg C.S., Crowley D.C., Wei W., and Gajarski R.J. Effect of age on lipid profiles in pediatric heart transplant recipients. Pediatr Transplant 9 (2005) 523-530
19. Seipelt I.M., Crawford S.E., Rodgers S., et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant 23 (2004) 317-322
20. Law Y.M., Yim R., Agatisa P., et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 25 (2006) 276-282
21. National Heart Lung and Blood Institute. The lipid research clinics population studies data book: the Prevalence Study (1980), U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD ; July
22. American Academy of Pediatrics. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89 (1992) 525-584
23. Kavey R.W., Daniels S.R., Lauer R.M., et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107 (2003) 1562-1566
24. National Heart Lung and Blood Institute. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Adult Treatment Panel III (full report) (2002), National Institutes of Health, Bethesda, MD
25. Libby P., and Tanaka H. The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts. Clin Transplant 8 (1994) 313-318
26. Lin H., Wilson J.E., Kendall T.J., et al. Comparable proximal and distal severity of intimal thickening and size of epicardial coronary arteries in transplant arteriopathy of human cardiac allografts. J Heart Lung Transplant 13 (1994) 824-833
27. Valantine H., Rickenbacker P., Kemna M., et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease. Circulation 103 (2001) 2144-2152
28. Holvoet P., Cleemput J.V., Collen D., and Vanhaecke J. Oxidized low-density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20 (2000) 698-702
29. Berenson G.S., Srinivasan S.R., Bao W., Newman III W.P., Tracy R.E., and Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338 (1998) 1650-1656
30. Tuzcu E.M., Kapadia S.R., Tutar E., et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults. Evidence from intravascular ultrasound. Circulation 103 (2001) 2705-2710
31. Addonizio L.J., Hsu D.T., Douglas J.F., et al. Decreasing incidence of coronary disease in pediatric cardiac transplant recipients using increased immunosuppression. Circulation 88 suppl (1993) II-224-II-229
32. Keys A., Arvanis C., and Blackburn H. Seven countries: a multivariable analysis of death and coronary heart disease (1980), Harvard University Press, Cambridge, MA 381
33. People's Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China: baseline report from the P.R.C.-U.S.A. Collaborative Study. Circulation 85 (1992) 1083-1096
34. Mahle W.T., Vincent R.N., Berg A.M., and Kanter K.R. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 24 (2005) 63-66
35. Chin C., Gamberg P., Miller J., Luikart H., and Bernstein D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant 21 (2002) 1213-1217
36. Penson M.G., Fricker F.J., Thompson J.R., et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 20 (2001) 611-618